The Battle for Frontline Therapy on MCL: Lenalidomide Plus Rituximab

(MedPage Today) -- At December's American Society of Hematology virtual meeting, researchers presented the 7-year long-term outcome analysis of the first study of a non-chemotherapy frontline treatment regimen with lenalidomide (Revlimid) plus...